ABSTRACT The mechanism of exercise-induced bronchoconstriction (EIB) was studied by observing the protective effects of several aerosol agents in a double-blind, randomised trial. Exercise-induced bronchoconstriction was not affected by placebo, but was reduced by each agent used (p < 0 001). Blocking the parasympathetic system had the weakest effect, while f2 adrenergic stimulation produced the strongest effect which was significantly different from the parasympatholytic (p < 0.02). The effect of the mast cell stabiliser, sodium cromoglycate (SCG) was found to be intermediate. However in some patients SCG had a stronger effect than the f2 adrenergic agonist. A relationship was found between EIB and bronchial hyperreactivity induced by histamine (p < 0 05).
Bronchial hyperreactivity to nonspecific stimuli is one of the hallmarks of asthma.1 2 This implies that bronchoconstriction occurs in asthmatics after inhalation of given concentrations of physical or chemical agents (allergens excepted) which would have no effect on healthy subjects. The degree of hyperreactivity is commonly estimated by bronchial sensitivity to histamine, acetylcholine, or methacholine. A strong correlation has been found between bronchial sensitivity to histamine and exercise-induced bronchoconstriction,3-5 and some authors4 consider that EIB is an expression of bronchial hyperreactivity.
The mechanism of EIB is at present incompletely understood. The parasympathetic nervous system, activated by sensory fibres situated in the mucosa of the large airways ("irritant receptors") seems to play a role, because aerosolised parasympatholytic agents6 or local anaesthetics7 may diminish or abolish EIB. Several studies8 point to the important influence of rapid ventilation with cold, dry air as the initiating stimulus which may trigger irritant receptors. f2 adrenergic agonists block EIB,6 which suggests that the sympathetic nervous system also plays a role. Sodium cromoglycate (SCG) often gives protection against EIB.9 This may indicate that mediator release from mast cells or from related histamine-containing cells in the bronchial lumen'0 is also involved. Some authors suggest that SCG may influence EIB in other ways.5 811 None of these suggestions has however been substantiated,5 and we have therefore assumed that the effect of SCG is brought about by mast cell stabilisation. 12 We have measured the protective effect of various agents in a group of asthmatic children who also had EIB. A 2 adrenergic agonist (fenoterol), a parasympatholytic agent (oxytropium bromide) as well as a mast cell stabiliser (SCG) were all tested as aerosols. In this way the contribution of the various parts of the autonomic nervous system and of mast cells in the mechanism of EIB has been studied. The bronchial sensitivity to histamine was also measured and related to the protective effect of the agents.
Methods
The group of asthmatics studied comprised nine boys and four girls (age range: 9 to 15-5 years, mean: 12-5 years). The The inhalation was performed as follows: after a submaximal expiration, the patient inspired synchronously with the aerosol, the mouth being kept closed over the inhaler opening. During this inspiration the tongue was kept on the floor of the mouth.
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After inspiration the breath was held for five seconds. The technique was learned using a placebo. The doses were chosen to obtain a maximal pharmacological effect.'5 17 The histamine threshold was determined by means of the inhalation of histamine acid phosphate in increasing concentration (doses 1, 2, 4, 8, 16, 32, and 64 mg/ml).18 At the beginning of the inhalation each patient performed a submaximal vital capacity manoeuvre, after which they inhaled the aerosol at tidal volume for 30 seconds. The time between the inhalations was three to five minutes. The histamine concentration which caused a decrease in FEV1 > 15% of the initial value was called the histamine threshold. With this technique the histamine threshold in healthy children is > 32 mg/ml.
An analysis of variance was done in order to detect any influences of day or agent sequence on the initial FEV1 (every day at 9 am and during the day) and the decrease of the FEV1 induced by exercise without protection (basal tests). The effects of the protective agents and comparisons between them were analysed using paired Student t tests. The relationship between the decrease in FEV, without agents and the degree of protection by each agent as well as the histamine threshold were analysed by linear regression equations from which p values were derived. The patient groups were divided according to the greatest effect by paired comparison between the three agents. These patient groups were compared according to initial FEV1, decrease in FEV1 induced by exercise without protection and the histamine threshold. The differences were analysed by Wilcoxon tests. Five per cent was taken as the level of significance.
All patients and their parents were fully informed about the aims and nature of the study and gave their consent.
Results
In the basal tests there were no correlations between day and agent sequences on the one hand and the initial FEV1 and the decrease in FEV1 in the basal tests on the other (analysis of variance). This makes the influence of variables other than the protective agents on the results improbable. The initial FEV1 values at 9 and 11 am did not change significantly except after the administration of the f2 adrenergic agonist when they were just significantly higher (p < 0 05).
The table shows the mean change in FEV1 after exercise both with and without protection for the group as a whole. The decrease in FEV1 without protection was 32x4 ± 3 0% and the results after placebo did not differ significantly. After admini- phase, we do not think this could have influenced the results significantly. The results were not influenced by variables other than the protective agents used and they are in accordance with those of other authors. 6 19 20 Individual patients differed in their responses to the various agents used. From the finding in some patients that the degree of protection given by the parasympatholytic exceeded that given by the mast cell stabiliser, it may be concluded that in these subjects activation of the vagus is more important than activation of the mast cell system. In contrast to the results of the patient group in general, some patients attained a greater degree of protection from the mast cell stabiliser than from the /2 adrenergic agonist. In these patients it can be assumed that mediator release from mast cells is relatively important in the mechanism of EIB. It seems that blocking of histamine release from their mast cells by triggering the /2 adrenergic receptors is only of limited value in contrast to the effect of SCG. Also, /2 adrenergic relaxation of their bronchial muscles is of relatively little importance in the blocking of the EIB response. Although this might indicate hyporesponsiveness of their /2 adrenergic receptors, this is unlikely because the bronchodilatation induced by the /2 adrenergic agonist under resting conditions in these patients was not less than in the others.
Our finding of a relationship between the degree of protection given by the parasympatholytic together with the mast cell stabiliser and the degree of bronchoconstriction without protection can be explained in two ways. Firstly, a combined mechanism involving both the parasympathetic nervous system and mast cells may operate in EIB. It was not possible to predict which was the dominant system from the initial lung function values, the bronchodilatation induced by the agents without exercise or the bronchial sensitivity to histamine. McFadden et a121 were also able to distinguish subgroups in their population with EIB and this may well be relevant to the choice of therapeutic agent. Secondly, a complete stabilisation of the mast cell, resulting in blocking of mediator release, may only occur if in addition to cromoglycate sensitive receptors the parasympathetic receptors of the mast cell are blocked as well. If it turns out that cromoglycate has effects outside mast cells then the interpretation of blocking studies such as ours will have to be reviewed. The blocking effect of cromoglycate might then be explained in part by an action on bronchial smooth muscle or irritant receptors. The important place of the mast cells in EIB is however supported by the observations that EIB is followed by a period of latency14 and that several authors2223 have found a rise in arterial histamine concentration after exercise.
The degree of bronchoconstriction induced by exercise has a strong relationship with the bronchial sensitivity to histamine as shown in this and other studies.4 5 This suggests that the mechanisms induced by both stimuli may be related. There is no difference in bronchial sensitivity to histamine in patients with EIB in whom the autonomic nervous system dominates compared with those in whom mast cells are ofmajor importance. Thus one might suspect that both these systems play a role in the mechanism leading to bronchoconstriction after histamine inhalation. Although the reaction to histamine could be confined to the direct stimulation of the histamine receptors of the bronchial muscle cells,24 this is probably not the case. Jackson et a125 showed in rats that the autonomic nervous system was stimulated by the histamine aerosol, since the bronchial response decreased after dissection of the vagus nerve. The study of Dixon et a/26 indicates that this may be caused by stimulation of irritant receptors. It seems probable that histamine-induced vagal stimulation also triggers mast cells, because the mast cell stabiliser SCG diminishes the bronchial response to histamine in some patients.27 28 The mechanisms by which histamine and exercise induce bronchoconstriction are similar and this justifies the view that EIB can be regarded as an expression of bronchial hyperreactivity.
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